We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

  • Home
  • About medac
  • Information for patients
  • Healthcare professionals
  • Products
  • Career opportunities
  • Media
  • Trecondi® - the new original from medac

    After 20 years of intensive research and development activity in the field of haematology and oncology, medac received EU-wide marketing authorisation for its new product Trecondi® (treosulfan) on 20 June 2019. medac‘s haematology portfolio is strengthened once again with this innovative therapeutic agent.

    Trecondi® is the first and only product containing treosulfan to have received marketing authorisation in Germany in haematology and therefore offers a new perspective compared with previous therapies.

    medac will begin the official sale of Trecondi® in Germany in August.

    Nach oben